Group Eleven Resources announced that re-analysis of drill samples from its Ballywire discovery in Ireland using a new sodium peroxide fusion assay method showed germanium grades 68% higher on average than previous tests. Germanium, a valuable semiconductor metal, was found in high concentrations alongside zinc, lead, silver, and copper. This improved accuracy highlights Ballywire's potential as a significant mineral deposit. The company is continuing its extensive drilling program with over 67,000 meters planned to further explore the site.
Group Eleven's Ballywire germanium grades update is offered alongside Pluang's Basic Materials sector snapshot for context. Among 31 US stocks in this sector, 28 rose and 3 fell as of Sep 17, 2026 17:11 WIB. Wheaton Precious Metals (WPM) led with a price of USD 149.97 and 100% buy orders, contrasting Kinross Gold (KGC) at USD 28.42 with 91% sell orders, while Freeport-McMoRan (FCX) showed a price of USD 70.70 with a balanced buy/sell split.
Broadcom, JPMorgan Chase, and Coca-Cola have each delivered substantial long-term returns through durable earnings and dividends. Broadcom benefits from booming AI semiconductor demand, projecting $230 billion revenue in fiscal 2028. JPMorgan Chase c...
Costco has partnered with DoorDash to offer same-day delivery across the United States, allowing members to order groceries, household essentials, electronics, and more from local Costco warehouses through the DoorDash app. This expands their existin...
Netflix Chief Content Officer Bela Bajaria revealed the company's strategy to focus on "unmissable" live sports events, including a potential package of international NFL games if available during future media rights negotiations. Netflix currently h...
Dryden Gold Corp. announced the discovery of visible gold in its first drill program at Mud Lake North, near Gold Rock, following high-grade surface samples from 2025. The initial three drill holes showed broad alteration zones with sulphide minerali...
OS Therapies has reached agreement with the FDA, MHRA, and EMA on an adaptive design for its Phase 3 trial of OST-HER2, a gene-edited cancer immunotherapy targeting metastatic osteosarcoma. The company will start this trial in late 2026 and plans a k...
